DABP Activators
DABP Activators are chemical compounds that enhance the biological activities of the DABP protein. These activators work by targeting specific biochemical pathways to upregulate the functional activity of DABP without altering gene expression or protein translation mechanisms. Each activator within this class operates through a distinct mechanism, which can involve the alteration of enzyme kinetics, modulation of co-factor availability, or changes in the protein's structural conformation that lead to an increased activity state. For instance, some DABP Activators may bind to allosteric sites on the protein, inducing a conformational change that results in a higher affinity for substrates or a decreased rate of deactivation. Others may interact with upstream regulators or components of signaling pathways that converge on DABP, potentiating its activity indirectly by fostering an environment that favors its active form.
The activation of DABP by these chemical compounds is often characterized by a cascade of intracellular events. A single activator might initiate the phosphorylation of secondary messengers that subsequently promote the activation of DABP. Alternatively, activation could stem from the inhibition of a negative regulator within the DABP pathway, thus relieving DABP from inhibitory pressures and enhancing its activity. While some activators directly interact with the protein to influence its active site dynamics, others may work by shifting the balance of cellular ions or small molecules, which in turn modulates DABP activity.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels, which in turn can enhance DABP activity through cAMP-dependent protein kinase (PKA) signaling pathways. PKA can phosphorylate various substrates that may include DABP or its associated proteins, leading to its activation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, leading to increased cAMP levels and enhanced PKA activity, thereby potentially increasing the phosphorylation and activation of DABP. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a catechin found in green tea with kinase inhibitory activity. It may enhance DABP function by inhibiting kinases that negatively regulate DABP or its signaling pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can modulate signaling pathways that phosphorylate and activate DABP or its associated proteins. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits glycogen synthase kinase-3 (GSK-3). Inhibition of GSK-3 may lead to the activation of signaling pathways that enhance DABP activity. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin acts as a JNK activator. By activating JNK signaling pathways, anisomycin may enhance DABP activity if DABP is regulated by JNK-mediated phosphorylation. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate is a histone deacetylase inhibitor that can lead to chromatin remodeling and affect the expression of proteins. It may indirectly enhance DABP activity by modulating the expression of proteins within DABP's signaling pathways. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase-4, which leads to increased cAMP levels and may enhance DABP activity through the cAMP/PKA signaling pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter signaling pathways downstream of PI3K, potentially leading to the enhancement of DABP activity due to changes in cellular signaling dynamics. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. Inhibition of p38 may shift the balance of cellular signaling in favor of pathways that activate DABP. | ||||||